Angiœdèmes héréditaires sur déficit en C1-inhibiteur : nouveautés thérapeutiques [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches]
Fiche du document
8 avril 2020
- doi: 10.53738/REVMED.2020.16.689.0675
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.689.0675
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32270933
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_5093AD1989988
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Blood--Plasma Plasma (Blood) Plasma Mediator RN 23602-78-0 Patientes Sang, Plasma du Plasma Plasma sanguinis Sciences de la gestion Gestion, Sciences de la Sciences de gestion Techniques de gestion Direction ManagementCiter ce document
F. Stehlin et al., « Angiœdèmes héréditaires sur déficit en C1-inhibiteur : nouveautés thérapeutiques [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.689.0675
Métriques
Partage / Export
Résumé
Hereditary angioedema type 1 and 2 are due to a deficiency in C1--esterase inhibitor. This molecule inhibits the generation of bradykinin, a potent inflammatory mediator that increases vascular permeability. Upon accumulation of bradykinin, patients affected develop painful subcutaneous or submucosal edemas that last for several days. In case the upper airways are affected, there is risk of suffocation. This type of angioedema does not respond to antihistamines, cortico-steroids or epinephrine. Management of angioedema attacks consists in injecting C1-esterase inhibitor concentrate or icatibant, a bradykinin receptor B2 antagonist. Preventive measures aim at reducing the frequency and the severity of angioedema attacks. Inhibition of -plasma kallikrein by lanadelumab, a monoclonal antibody adminis-tered subcutaneously, is effective and well tolerated.